DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 04 · Volume 42 · July 2009 DOI: 10.1055/s-002-19289

Original Paper

  • 129
    Zhang, Y.; Lehmann, M.; Shobeiry, A.; Höfer, D.; Johannes, S.; Emrich, H. M.; Dietrich, D. E.:

    Effects of Quetiapine on Cognitive Functions in Schizophrenic Patients: A Preliminary Single-trial ERP Analysis

  • 135
    Suarez, D.; Haro, J. M.; Novick, D.; Perrin, E.; Ochoa, S.; Naber, D.:

    Reasons and Outcomes of Olanzapine Dose Adjustments in the Outpatient Treatment of Schizophrenia

  • 141
    Neuhaus, A. H.; Opgen-Rhein, C.; Urbanek, C.; Hahn, E.; Ta, T. M. T.; Seidelsohn, M.; Strathmann, S.; Kley, F.; Wieseke, N.; Sander, T.; Dettling, M.:

    COMT Val158Met Polymorphism is Associated with Cognitive Flexibility in a Signal Discrimination Task in Schizophrenia

  • 145
  • 153
  • 158
    Berwaerts, J.; Cleton, A.; Herben, V.; Vliet, I. van de; Chang, I.; Hoek, P. van; Eerdekens, M.:

    The Effects of Paroxetine on the Pharmacokinetics of Paliperidone Extended-release Tablets

  • Letter

  • 164
  • 166
    Englisch, S.; Weinbrenner, A.; Inta, D.; Zink, M.:

    Aripiprazole for the Management of Olanzapine-induced Weight Gain